VINCRISTINE SULFATE INJECTION SOLUTION

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Bahan aktif:

VINCRISTINE SULFATE

Tersedia dari:

ACCORD HEALTHCARE INC

Kode ATC:

L01CA02

INN (Nama Internasional):

VINCRISTINE

Dosis:

1MG

Bentuk farmasi:

SOLUTION

Komposisi:

VINCRISTINE SULFATE 1MG

Rute administrasi :

INTRAVENOUS

Unit dalam paket:

2ML

Jenis Resep:

Prescription

Area terapi:

ANTINEOPLASTIC AGENTS

Ringkasan produk:

Active ingredient group (AIG) number: 0107646001; AHFS:

Status otorisasi:

CANCELLED PRE MARKET

Tanggal Otorisasi:

2017-08-07

Karakteristik produk

PRODUCT MONOGRAPH
PR
VINCRISTINE SULFATE INJECTION
USP
1 mg/mL
Antineoplastic Agent
Accord Healthcare Inc.
3100 Steeles Avenue East,
Markham, ON, L3R 8T3
Canada
Date of Revision: February 4, 2013
CONTROL # 160953
1
PRODUCT MONOGRAPH
Pr
Vincristine Sulfate Injection
USP
1 mg/mL
THERAPEUTIC CLASSIFICATION
Antineoplastic Agent
WARNINGS
CAUTION:
VINCRISTINE
SULFATE
INJECTION
IS
A
POTENT
DRUG
AND
SHOULD
BE
USED
ONLY
BY
PHYSICIANS
EXPERIENCED
WITH
CANCER
CHEMOTHERAPEUTIC DRUGS. BLOOD COUNTS SHOULD BE TAKEN ONCE OR
TWICE WEEKLY. DISCONTINUE OR REDUCE THE DOSAGE UPON EVIDENCE
OF ABNORMAL DEPRESSION OF THE BONE MARROW.
THIS PREPARATION SHOULD BE ADMINISTERED BY INDIVIDUALS EXPERIENCED IN
THE ADMINISTRATION
OF VINCRISTINE SULFATE INJECTION. IT IS EXTREMELY IMPORTANT THAT THE
INTRAVENOUS NEEDLE OR
CATHETER
BE
PROPERLY
POSITIONED
BEFORE
ANY
VINCRISTINE
IS
INJECTED.
LEAKAGE
INTO
SURROUNDING TISSUE DURING INTRAVENOUS ADMINISTRATION OF VINCRISTINE
SULFATE INJECTION MAY
CAUSE CONSIDERABLE IRRITATION. IF EXTRAVASATION OCCURS, THE INJECTION
SHOULD BE DISCONTINUED
IMMEDIATELY, AND ANY REMAINING PORTION OF THE DOSE SHOULD THEN BE
INTRODUCED INTO ANOTHER
VEIN. LOCAL INJECTION OF HYALURONIDASE AND THE APPLICATION OF MODERATE
HEAT TO THE AREA OF
LEAKAGE HELP DISPERSE THE DRUG AND ARE THOUGHT TO MINIMIZE DISCOMFORT
AND THE POSSIBILITY
OF CELLULITIS.
FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES. SEE
'WARNINGS" SECTION FOR THE TREATMENT OF PATIENTS GIVEN INTRATHECAL
VINCRISTINE SULFATE
INJECTION.
ACTION AND CLINICAL PHARMACOLOGY
The complete mode of action of Vincristine Sulfate Injection is
unknown.
_In vitro _
investigations
have demonstrated that vincristine is a spindle inhibitor. This
inhibition has been linked to a
reversible binding of the drug to microtubule and spindle proteins in
S phase. Vincristine has
also been associated with an Interference of RNA synthesis. Whether as
a result or independent
of these actions, vincristine has been shown to arrest cells in
metaphase.
Pharmacokinetic studies in patients with ca